Cargando…
Cost-effectiveness evaluation of escitalopram in major depressive disorder in Italy
BACKGROUND: Depression has a lifetime prevalence of 10%–25% among women and 5%–12% among men. Selective serotonin reuptake inhibitors (SSRIs) are the most used and the most cost-effective treatment for long-term major depressive disorder. Since the introduction of generic SSRIs, the costs of branded...
Autores principales: | Mencacci, Claudio, Di Sciascio, Guido, Katz, Pablo, Ripellino, Claudio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570079/ https://www.ncbi.nlm.nih.gov/pubmed/23413176 http://dx.doi.org/10.2147/CEOR.S39492 |
Ejemplares similares
-
C-QUALITY: cost and quality-of-life pharmacoeconomic analysis of antidepressants used in major depressive disorder in the regional Italian settings of Veneto and Sardinia
por: Mencacci, Claudio, et al.
Publicado: (2013) -
Cost-Effectiveness of Asenapine in the Treatment of Patients with Bipolar I Disorder with Mixed Episodes in an Italian Context
por: Caresano, Chiara, et al.
Publicado: (2014) -
Comparative efficacy of escitalopram in the treatment of major depressive disorder
por: Ali, Mazen K, et al.
Publicado: (2011) -
Expected effects of COVID-19 outbreak on depression incidence in Italy
por: Mencacci, Claudio, et al.
Publicado: (2021) -
Reproducibility of the Efficacy of Escitalopram in Patients with Major Depression Who Had Previously Remitted with Escitalopram
por: Yoshimura, Reiji, et al.
Publicado: (2021)